AHA: Amgen's Repatha tied to greater risk reduction in high-risk heart attack patients

Amgen's Repatha may already be far ahead in the PCSK9 field, but new competition is on its way. A new analysis in high-risk heart attack patients could give it some more ammo for that fight.